



ASCO 2015

LUNG CANCER


TWITTER COVERAGE

LUNG CANCER TWITTER VOLUME TRENDS




TYPES OF LUNG CANCER

(By number of tweets)




BIOMARKERS

(By number of tweets)




LUNG CANCER AUTHOR CATEGORIZATION




*Authors who tweeted frequently about health care topics
 **Authors who cannot be classified into any major stakeholder group

KEY CLINICAL STUDIES ON LUNG CANCER

(By number of tweets)



HCP SENTIMENT AROUND KEY STUDIES ON LUNG CANCER



67% of HCPs ...
 ... tweeting about the **CheckMate 057** trial were impressed by the **Overall Survival**.
 HCPs were excited about adopting **Nivo** as the 2L non-squam **standard of care**.
 Mixed reaction in HCPs about the study due to improved outcomes in **PD-L1+** patients only.

KEYNOTE-028
 Overall Response rate of **35%** was considered promising by HCPs.
 HCPs were concerned that a **low percentage of patients** were eligible for the PD-L1+ based trial.

TOP INFLUENTIAL HCPs FOR LUNG CANCER

